naira, Bioshares did not really get the complete picture and I...

naira,
Bioshares did not really get the complete picture and I would imagine if they do a follow up article they will sing a different tune.
Forrest is corect in that the main product now going forward, in tube, the 3rd gen test for the QFT platform, is patent protected until 2023.
My understanding is that the in tube system not only applies to the latent TB test but is also available for the 5 or 6 other tests which are either in the pipeline or already ready to be commercialised.

CST shareholders are in the hands of two directors who are excellent scientists so I am content to allow them to stitch up the patent side. From time to time they have been criticised for not spruiking the company enough, actually I am very happy they don't do that as very shortly the revenue and profit figures will speak far louder than any transitionary spruiking could do.

Yes they could possibly do a small acquisition but if so my money would be that it would be an excellent buy, particularly in the present trying conditions where many small companies worldwide, often through no fault of their own, are starved of capital.
If there is no acquisition and the war chest builds up to $25million, $35million, or whatever, great. In these economic conditions for a small company to have no debt and a very solid credit in the bank that has to be pretty unique and good stuff for shareholders.

Pending the ability to pay fully franked dividends in 2009/10 I wouldn't mind seeing a small share buyback using say one third of available cash, with the majority of shares tightly held a reduction of shares on issue has only to be of benefit to all shareholders.

regards, EB